Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. - Wikidata - wikimedia - TriplyDB

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.

http://www.wikidata.org/entity/Q33387521

about

Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours Thrombopoietin mimetics for patients with myelodysplastic syndromes Clinical indications for thrombopoietin and thrombopoietin-receptor agonists Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes Eltrombopag for the treatment of aplastic anemia: current perspectives Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.Thrombocytopenia in patients with myelodysplastic syndromes.Toxicities of the thrombopoietic growth factors Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome.Eltrombopag for the treatment of immune thrombocytopenia.The efficacy of romiplostim in the treatment of severe thrombocytopenia associated to Evans syndrome refractory to rituximab.Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia.Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.Supportive care for thrombocytopenia in patients receiving treatment for myelodysplasia: a challenge for the future.Positioning new treatments in the management of immune thrombocytopenia A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide.Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside.Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists.Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation.Valproic acid for the treatment of low-risk myelodysplastic syndromes: A case report and a review of the literature.Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome.Management of thrombocytopenia due to liver cirrhosis: a review Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials.Thrombopoiesis-stimulating agents and myelodysplastic syndromes.Use of romiplostim in patients with chronic idiopathic thrombocytopenic purpura during perioperative period.Romiplostim in the management of the thrombocytopenic surgical patient.Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.New treatments for myelodysplastic syndromes

P2860

Q24186714-1345F22A-1C3F-47E2-8D82-9D4B0FEFFB0B Q24198060-E721CFF4-3950-4DC6-82F0-01C73EA8538D Q24601161-2198EA3D-0D43-4943-A55E-1CC584C69776 Q26863182-CCC598B6-E2F4-4882-8617-3BE06F42F821 Q28071710-6B463935-2BE3-4C51-9360-11B333E544C4 Q30248355-0C613E8F-67ED-44D1-8889-44A51F1A7E8C Q30399669-E82BF9D2-B5DD-4536-81AC-6B3061735B1C Q33390639-427CFD91-A7C6-4B98-A965-7BA6D8133344 Q33390645-9B412B6E-5943-4E9D-8B1C-E7D0A97FF999 Q33390778-96E4929D-5E79-410B-84CE-3E2721E721DA Q33392293-C77C97F3-EC2A-4DEA-BC09-8BB1DC0892F7 Q33395333-792CF773-918E-44DD-85AF-18EFA66009E9 Q33395648-39D88FAE-FA4A-4773-A53D-50F241125C35 Q33395776-D3CE5EF3-E8A7-4C8F-87B3-E439B8422E15 Q33396033-8DE460B6-1A59-475A-8F3F-6FA67DAF29B1 Q33397092-04B77009-9CE0-4859-8322-02E64881035D Q33398217-0A9D77C4-3823-46CC-B046-03D1EE56E369 Q33398815-4D1088FC-D9CC-4082-A6B6-E74042502F66 Q33401421-3A9FF50B-5CF7-4B60-BBCE-8D510D83D0C2 Q33402882-C78FBB46-2004-4A9D-97BB-1499C352FCC3 Q33403765-8C0737B3-7062-448A-9209-F421413235ED Q33404095-A4738510-579E-415C-8644-94C25418C4CC Q33404600-8DADA26D-7342-4708-BD66-FA6702C2DDC6 Q33407110-A299AE23-20BE-4EEE-8289-9C2E834EF572 Q33407443-A0C9F1AC-DBF8-4F20-B3E9-0A31CA45599D Q33410123-E91F32EC-A251-435F-9134-EC28576A8BAE Q33412339-3650EBC9-ADC1-41B9-BEF5-6DE88AB702A1 Q33413436-3CC365D4-BE7A-4B0F-83CA-159A133C3F32 Q33413924-ABF1606E-C3EF-453C-A1BB-6C999B32B854 Q33414087-E1AE2DCD-CAAA-4CC9-8921-D96D031F4C7D Q33416541-F942A613-BD58-400E-A71F-816C0590F62C Q33417304-79A2D317-F779-4B7B-9EDF-E8ED784733B5 Q33420207-D7B8590E-0987-497E-8010-9A3A5745BA0D Q33422277-D59FBADB-AF2E-4DAC-B6E1-B797D492242B Q33423291-64346B76-CBDF-4D92-AE03-FFDF9979C673 Q33427023-6B66C47E-C3BF-4CD0-8201-D43C5811494E Q33436416-DFD39802-9D71-4484-AB73-864CB8F28184 Q33442715-CC82AF47-089F-4907-B9C4-0A8153185E5F Q34392449-9BC2EF8B-BB77-43D3-B6A4-246FCB51AA31 Q34549290-35D60DB3-C973-4825-8E7F-E6910BC672E1

P2860

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.

http://www.wikidata.org/entity/Q33387521

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Safety and efficacy of romiplo ...... syndrome and thrombocytopenia.

@ast

Safety and efficacy of romiplo ...... syndrome and thrombocytopenia.

@en

type

label

Safety and efficacy of romiplo ...... syndrome and thrombocytopenia.

@ast

Safety and efficacy of romiplo ...... syndrome and thrombocytopenia.

@en

prefLabel

Safety and efficacy of romiplo ...... syndrome and thrombocytopenia.

@ast

Safety and efficacy of romiplo ...... syndrome and thrombocytopenia.

@en

P1433

Q33387521-8C066812-30D4-4CBB-8F3C-A9DE27275AE2

P1476

Q33387521-1C7A20BC-A9DE-4001-B232-6B5C08CC36DA

P2093

Q33387521-1693B3AA-024C-40D5-911E-14BBE6F137EE

Q33387521-2369D332-44F7-43F3-B56E-9C603B6B33E9

Q33387521-25AD4552-06A2-4B55-8BE2-3995C28CE8C9

Q33387521-2AAA37B9-DCAF-4339-B403-ED8A6F0D3FE3

Q33387521-382DB95B-E580-4817-B954-F6D04E61445D

Q33387521-3A1F7812-25B8-40B1-9B75-EBADED1C4957

Q33387521-45CDA612-A67E-41DD-8B0C-2E053F9DBA22

Q33387521-66F8869A-AD22-4BB0-847D-44B4596F7A4A

Q33387521-DC26BC84-CF08-4633-BF0C-7EA48C1C03E1

Q33387521-DE6059B5-BCDF-46AB-9BDB-702EA80D9A1F

P304

Q33387521-1877499E-73AA-4D7C-9A85-3742887270F2

P31

Q33387521-077632E9-8A62-4ED6-9DD1-44DE7FF86F12

P356

Q33387521-F28EA021-8B81-4238-822E-A832310F5A77

P407

Q33387521-4FC20D36-9CE8-43F0-A010-6FB9380CD8D2

P433

Q33387521-06FE6D46-B975-4AF3-A7BC-751D4013C782

P478

Q33387521-D04AFA92-5F9E-494B-93A8-D56199C369A5

P50

Q33387521-107F622A-FEA8-4ED0-B2E9-A560F27C8C36

Q33387521-57416C17-2A1B-463A-822B-FF1597C741EC

Q33387521-7E1BE99F-E96E-47B4-841F-4B1AAC0FD009

Q33387521-B03938DF-5604-46C7-8D05-C94546594C47

Q33387521-DC944A93-EB13-4457-B5DD-63DA519092C9

P577

Q33387521-8F41B4CD-35BE-4DA3-B052-A7DD390918F9

P5875

Q33387521-FB2B1ACD-EBFB-4BE6-8E44-C3E9348DF690

P698

Q33387521-9FE35547-B1BA-48E7-9C14-C7AC82D246B2

P921

Q33387521-EDF30B4E-B3A7-43A3-AE0C-F357AFAFDB99

P356

JCO.2009.24.7999

P1433

Journal of Clinical Oncology

P1476

Safety and efficacy of romiplo ...... syndrome and thrombocytopenia.

@en

P2093

Adam Boruchov

http://www.w3.org/2001/XMLSchema#string

David Bowen

http://www.w3.org/2001/XMLSchema#string

Dietmar P Berger

http://www.w3.org/2001/XMLSchema#string

Eva Hellstrom-Lindberg

http://www.w3.org/2001/XMLSchema#string

Jamile Shammo

http://www.w3.org/2001/XMLSchema#string

Janet Franklin

http://www.w3.org/2001/XMLSchema#string

Kuolung Hu

http://www.w3.org/2001/XMLSchema#string

Mikkael A Sekeres

http://www.w3.org/2001/XMLSchema#string

Pamela S Becker

http://www.w3.org/2001/XMLSchema#string

Robert Siegel

http://www.w3.org/2001/XMLSchema#string

P304

437-444

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.24.7999

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Eva Hellström-Lindberg

Richard A. Larson

Hagop Kantarjian

P577

2009-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40686351

http://www.w3.org/2001/XMLSchema#string

P698

20008626

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia